In Vivo Non-viral CAR-T Cell Engineering Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview of In Vivo CAR-T Cell Engineering

Currently, CAR-T therapy using ex vivo-generated cells poses multiple barriers associated, being complicated and expensive to manufacture, and with a high risk of toxicity. Therefore, in vivo CAR-T Cell Engineering is a potential solution with the ease of production and the possibility of standardization. Furthermore, studies have shown that in vivo CAR-T Engineering is associated with a reduced risk of the most common toxicities, such as CRS, and "on-target, off-tumor" toxicity.

Fig.1 CAR-T-cell generation in situ or ex vivo. (Olweus, 2017)

Our In Vivo Non-viral CAR-T Cell Engineering Services

The rapid development of non-viral delivery systems has brought new perspectives to the design of in vivo CAR-T cell engineering. The non-viral delivery system has many advantages, its processing can take a variety of optimized formulations, and its synthesis is more streamlined, enabling precise drug delivery, reducing toxicity, and increasing the targeting of in vivo CAR-T therapeutics. Powered by years of experience in the CAR-T field, Creative Biolabs possesses strong capabilities in providing in vivo non-viral CAR-T Cell engineering services to facilitate customers' projects. There are some of our featured services as follows for reference, meanwhile, we also provide highly-customized in vivo non-viral CAR-T Cell engineering services to help global customers.

In Vivo IVT mRNA-based CAR-T Cell Engineering Service

In Vivo Circular RNA-based CAR-T Cell Engineering Service

Package Service

We provide one-stop in vivo non-viral CAR-T cell engineering services to assist clients' projects, here are several prominent services you can refer to:

Published Data

Here are some results displaying the in vivo non-viral CAR-T cell engineering as a potentially ideal solution for tumor immunotherapy.

*1. In situ* CAR-T programming using synthetic DNA nanocarriers.**

Fig.2 Design and manufacture of DNA nanocarriers for in vivo CAR-T programming. (Smith, et al., 2017)	Fig.3 In vitro cytotoxicity assay of nanoparticle-transfected T cells against leukemia cells. (Smith, et al., 2017)
2. In situ CAR-T programming using IVT mRNA nanocarriers.

Fig.4 Design and manufacture of IVT mRNA nanocarriers for in vivo CAR-T programming. (Parayath, et al., 2020)	Fig.5 In vitro cytotoxicity assay of nanoparticle-transfected T cells against Raji lymphoma cells. (Parayath, et al., 2020)

Frequently Asked Questions

Q1. Whether in vivo non-viral CAR engineering solution can be applied to other cells?

A: In vivo non-viral CAR-T cell engineering has many potential directions of application, such as in situ CAR-NK cells programming using the non-viral delivery system, in suit CAR-M cells programming.

Q2. What are the advantages of the non-viral approach comparing the viral-based approach for in vivo CAR-T engineering?

Types of Vector		Pros	Cons
Non-viral vector	Lipid-based nanoparticles	Simple manufacturing process	Low transfection efficiency
	Polymer-based nanoparticles	High genetic cargo capacity	Toxicity related to materials
	Inorganic nanoparticles	Low immunogenicity
Viral vector	Adenovirus	High transfection	Limited genetic cargo capability
	Retrovirus	efficiency	Immunogenicity
	Lentivirus	High stability of expression	Host genome integration

Professional consultation provides you with guidance throughout the entire project process, please contact us for a tailored solution.

References

Olweus, J. Manufacture of CAR-T cells in the body. Nat Biotechnol. 2017, 35, 520–521.
Smith, T.T.; et al. In situ programming of leukemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017, 12(8):813-820.
Parayath, N.N.; et al In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020, 11(1):6080.